Asianet NewsableAsianet Newsable

First day of COVID-19 vaccination drive successful; few adverse events reported from Delhi, WB

However, the first day of the Covid-19 vaccination drive saw one case of a severe adverse event in Delhi necessitating medical treatment at a dedicated centre at the All India Institute of Medical Sciences, Delhi.

First day of COVID-19 vaccination drive successful; few adverse events reported from Delhi, WB-dnm
Author
New Delhi, First Published Jan 17, 2021, 10:40 AM IST

New Delhi: India on Saturday successfully conducted the first day of the first phase of nationwide Covid-19 vaccine drive, which is being called as the world’s largest vaccination drive so far.

As many as 1,91,181 healthcare and frontline workers received the first dose. The vaccination drive was carried out by 16,755 personnel held across the country during 3,352 sessions. Apart from healthcare and frontline workers, an additional 3,429 people from defence institutions of the Indian Army and the Indian Navy, were also immunised.

However, the first day of the Covid-19 vaccination drive saw one case of a severe adverse event in Delhi necessitating medical treatment at a dedicated centre at the All India Institute of Medical Sciences, Delhi.

A security guard who was administered a shot of Covaxin at AIIMS on Saturday was admitted at the hospital after he developed an allergic reaction as part of "severe" adverse events following immunisation.

According to AIIMS Director Randeep Guleria, the security guard, in his 20s, at AIIMS who received the jab after 4 pm, complained of palpitations and developed an allergic skin rash within 15-20 minutes after being inoculated and was admitted to the ...

In another case, a 35-year-old nurse was admitted to the critical care unit (CCU) of a hospital in Kolkata after she lost consciousness within minutes of taking the COVID-19 vaccine on Saturday, officials said.

Thirteen other 'Adverse Event Following Immunisation' (AEFI) cases were also reported from various parts of the state but those were not serious, they said.

The Centre said that Serum Institute of India's Covishield was supplied to all states and UTs while Covaxin developed by Bharat Biotech was used by 12 states.

According to the World Health Organisation (WHO), any untoward medical occurrence which follows immunisation and does not necessarily have a causal relationship with the usage of the vaccine, is known as AEFI.

Follow Us:
Download App:
  • android
  • ios